Literature DB >> 2840230

Renal tubular function in patients treated with high-dose cisplatin.

G Daugaard1, U Abildgaard, N H Holstein-Rathlou, I Bruunshuus, D Bucher, P P Leyssac.   

Abstract

The effect of three cycles of high-dose cisplatin (40 mg/m2 day for 5 days) on renal tubular function was evaluated in 30 patients. A significant impairment of proximal tubular salt and water reabsorption rates was observed, but also distal tubular function seemed to be affected. These changes were also present 6 months after termination of treatment. Sodium and magnesium clearance increased significantly during treatment. Magnesium clearance normalized shortly after treatment but sodium clearance was significantly elevated 6 months after treatment. Proteinuria, albuminuria, and amino aciduria, together with an increase of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) excretion rates, were observed during each treatment cycle. A good correlation was registered between the increase in urinary excretion rates of protein, NAG, and magnesium and the decrease in proximal tubular salt and water reabsorption during cisplatin administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840230     DOI: 10.1038/clpt.1988.132

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

Review 1.  Biomarkers of Drug-Induced Kidney Toxicity.

Authors:  Benjamin R Griffin; Sarah Faubel; Charles L Edelstein
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

2.  Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.

Authors: 
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

3.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.

Authors:  C R Thomas; K J Stelzer; J G Douglas; W J Koh; L V Wood; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

Review 4.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.

Authors:  G Milano; V Troger; A Courdi; X Fontana; P Chauvel; J L Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.

Authors:  Blessy George; Melanie S Joy; Lauren M Aleksunes
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-12

7.  Usefulness of Pseudocontinuous Arterial Spin-Labeling for the Assessment of Patients with Head and Neck Squamous Cell Carcinoma by Measuring Tumor Blood Flow in the Pretreatment and Early Treatment Period.

Authors:  N Fujima; D Yoshida; T Sakashita; A Homma; A Tsukahara; K K Tha; K Kudo; H Shirato
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

8.  Investigation of the efficacy of 99 mTc-DTPA scintigraphic GFR measurement with Gates method in the detection of cisplatin-induced nephrotoxicity in comparison with plasma urea and creatinine measurement.

Authors:  Filiz Özülker; Tamer Özülker; Aysun Küçüköz Uzun; Tevfik Özpaçacı
Journal:  Med Oncol       Date:  2010-05-14       Impact factor: 3.064

9.  Magnesium metabolism and its disorders.

Authors:  R Swaminathan
Journal:  Clin Biochem Rev       Date:  2003-05

10.  Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity.

Authors:  E Ozdemir; A I Dokucu; A K Uzunlar; A Ece; M Yaldiz; H Oztürk
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.